Reliability of the Norwegian version of PainDETECT: a test-retest study

Figures & data

Figure 1. The process of inclusion and exclusion.

Table 1. Overview of the participants’ characteristics, N = 67.

Age, y, mean (SD)	57 (14.3)
Female/male (n)	48/21
Symptom duration, months, mean (SD)	127 (171)
Diagnosis, n (%)^a
Back pain	12 (14.6)
Knee pain	10 (12.2)
Shoulder pain	9 (11.0)
Neck pain	7 (8.5)
Neurological disorders	7 (8.5)
Backpain with radiating pain	6 (7.3)
Hip pain	6 (7.3)
Rheumatic disorders	6 (7.3)
Headache	2 (2.4)
Others^b	17 (20.7)
Medications, n (%)^c,d
Cardiovascular agents	45 (29.8)
Analgesics	32 (21.2)
Anti-inflammatory agents	16 (10.6)
Respiratory tract agents	16 (10.6)
Anticonvulsants	14 (9.3)
Antidepressants	11 (7.3)
Gastrointestinal agents	7 (4.6)
Hormonal agents	4 (2.6)
Blood glucose regulators	2 (1.3)
Metabolic bone disease agents	2 (1.3)
Antineoplastics	1 (0.7)
Immunological agents	1 (0.7)

^aThe total number is higher than the number of participants included as some have more than one diagnosis.

^bIncludes i.e. central sensitisation, diabetes, fibromyalgia, medial epicondylitis and pelvic pain.

^cMedications divided into subgroups.

^dThe total number is higher than the number of participants as some use multiple medications.

Table 2. Missing answers PD-Q, N = 67.

Question	Missing answers, n (%)
Part 1
Current pain	0 (-)
Strongest pain the past 4 weeks	1 (1.5)
Average pain the past 4 weeks	2 (3.0)
Part 2
Pain drawing	1 (1.5)
Radiating pain	13 (19.4)
Part 3
Pain patterns	6 (8.9)
Part 4
Burning sensation	3 (4.5)
Tingling/prickling sensation	0 (-)
Sensitivity for light touch	0 (-)
Sudden pain attacks (electric shock)	1 (1.5)
Heat/cold sensitivity	0 (-)
Numbness	0 (-)
Presser-evoked pain	1 (1.5)

Table 3. Test-retest reliability of pain intensity, N = 67.

Pain intensity	Current pain	Max pain past 4 weeks	Average pain past 4 weeks
N	67	66	65
PD-Q pre
Mean (SD)	3.8 (2.0)	7.2 (1.9)	4.9 (1.8)
PD-Q post
Mean (SD)	4.1 (2.2)	7.2 (1.9)	4.8 (1.8)
ICC (95% CI)	0.76 (0.64–0.85)	0.78 (0.67–0.86)	0.70 (0.55–0.80)
SEM	1.07	0.90	1.02

SD: standard deviation; CI: confidence interval; SEM: standard error measurement.

Table 4. – Test-retest reliability of separate items in part 2, 3 and 4, N total = 67.

Question	Kappa (95% CI)	N
Part 2
Radiating pain	0.71 (0.51–0.91)	55
Part 3
Pain patterns	0.59 (0.43–0.74)	62
Part 4
Burning sensation	0.49 (0.34–0.64)	64
Tingling/prickling sensation	0.50 (0.35–0.64)	67
Sensitivity for light touch	0.37 (0.21–0.53)	67
Sudden pain attacks (electric shock)	0.36 (0.22–0.50)	66
Heat/cold sensitivity	0.50 (0.33–0.67)	67
Numbness	0.37 (0.22–0.51)	67
Pressure-evoked pain	0.35 (0.20–0.50)	66

Table 5. Overview of percentage of agreement of separate items in part 2, 3 and 4, N total = 67.

Question	N	Agreement, N (%)
Part 2
Radiating pain	55	50 (91)
Part 3
Pain patterns	62	43 (69)
Part 4
Burning sensation	64	39 (61)
Tingling/prickling sensation	67	41 (61)
Sensitivity for light touch	67	39 (58)
Sudden pain attacks (electric shock)	66	33 (50)
Heat/cold sensitivity	67	49 (73)
Numbness	67	33 (49)
Pressure-evoked pain	66	31 (47)

Table 6. Overview of the PD-Q screening data, N = 52, Kappa = 0.50 (95% CI 0.31–0.69).

	Screening categories PD-Q (post)
	Unlikely	Ambiguous	Likely	Total
Screening categories PD-Q (pre)
Unlikely	22	4	1	27
Ambiguous	3	8	3	14
Likely	1	4	6	11
Total	26	16	10	52